News and Insights

By Timothy Visich We  partnered with Merck & Co., Inc and Samsung Bioepis and conducted a  simulated-use  comparative study on two autoinjectors used for the treatment of rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is often treated by effective biologics delivered in different types of injection devices. RA patients, who are often limited in dexterity capabilities, are sometimes prescribed self-injection devices to deliver injections on themselves. Using an injection device for self-delivery can be a hard task for RA patients to complete, and even painful depending on the device being used. Recently, Merck & Co., Inc and Samsung Bioepis have developed the Brenzys autoinjector with the goal of improving the self-injection experience for RA patients. Brenzys (left) and Enbrel (right) While delivering a biosimilar of etanercept (Enbrel), the Brenzys device offers the following advantages: Eliminates the need for pressing down on an injection button with the thu

By Naomi Cherne I was recently on an online forum for a touchscreen product because I was frustrated by a problem I kept having and the lack of any means to solve this problem (hey, did you know that toddlers like to touch interactive screens?). The company had a “feature suggestion” forum for its products and, sure enough, there was a post requesting a touchscreen lock feature. I clicked through to add my support for the request, and was confronted with pages and pages of ire. It seemed that the company had quickly released a new feature that met the original poster’s need but was not a touchscreen lock, and had marked the post as “Solved”. Hundreds of posters begged to differ, offering up use scenarios where the lack of a touchscreen lock prevented the intended use of the product, as well as a stream of anger towards the company, statements that they had returned the product, and descriptions of the competitor products they planned to purchase instead. When people could not